Study of dostarlimab and bevacizumab for recurrent clear cell cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of recurrent clear cell carcinoma of the ovary, endometrium, cervix, vagina, or vulva.
- You have had 1 to 5 previous treatments for your cancer.
- Your cancer progressed within 12 months of completing platinum-based chemotherapy.
- You are well enough to be up and about (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You are willing to have a fresh tumor biopsy and provide a tissue sample from a previous biopsy or surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This trial tests a combination of two drugs—dostarlimab (an immunotherapy) and LB-100 (a new drug targeting a protein called PP2A)—for people with clear cell ovarian cancer that has returned or is resistant to platinum chemotherapy. The goal is to see if this combination is safe and effective for this specific type of cancer.
This trial tests a combination of three drugs (RC48, AK104, and bevacizumab) for ovarian clear cell carcinoma, a type of ovarian cancer. The goal is to see if this combination can help shrink or control the cancer in people who have not had many prior treatments.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.